News Ratings For Deciphera Pharmaceuticals Daily News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from News ratings for deciphera pharmaceuticals daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In News Ratings For Deciphera Pharmaceuticals Daily Today - Breaking & Trending Today

Deciphera Pharmaceuticals (NASDAQ:DCPH) Sets New 12-Month High at $25.59

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report)’s stock price hit a new 52-week high during trading on Monday . The company traded as high as $25.59 and last traded at $25.58, with a volume of 366347 shares changing hands. The stock had previously closed at $25.57. Analysts Set New Price Targets A number of […] ....

United States , Charles Schwab Investment Management Inc , Deciphera Pharmaceuticals Price Performance , Institutional Trading Of Deciphera Pharmaceuticals , Deciphera Pharmaceuticals , Deciphera Pharmaceuticals Inc , Principal Financial Group Inc , Jefferies Financial Group , Deciphera Pharmaceuticals Company Profile , Deutsche Bank , Jpmorgan Chase Co , News Ratings For Deciphera Pharmaceuticals Daily , Get Free Report , Financial Group , Schwab Investment Management , Investment Management , Dark Forest Capital Management , Forest Capital Management , Deciphera Pharmaceuticals Daily ,

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives $24.17 Average Price Target from Brokerages

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) have been assigned a consensus recommendation of “Hold” from the ten brokerages that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month […] ....

United States , Deciphera Pharmaceuticals Inc , Deciphera Pharmaceuticals Stock Performance , Deciphera Pharmaceuticals , Institutional Trading Of Deciphera Pharmaceuticals , News Ratings For Deciphera Pharmaceuticals Daily , Deutsche Bank , Deciphera Pharmaceuticals Company Profile , Analyst Recommendations For Deciphera Pharmaceuticals , Deerfield Management Companylp Series , Jpmorgan Chase Co , Fisher Asset Management , Get Free Report , Asset Management , Forest Capital Management , Trexquant Investment , Get Free , Deciphera Pharmaceuticals Daily ,

Zacks Research Weighs in on Deciphera Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:DCPH)

Zacks Research Weighs in on Deciphera Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:DCPH)
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United States , Zacks Research , Hedge Funds Weigh In On Deciphera Pharmaceuticals , News Ratings For Deciphera Pharmaceuticals Daily , Principal Financial Group Inc , Jpmorgan Chase Co , Deciphera Pharmaceuticals Inc , China Universal Asset Management Co , Jefferies Financial Group , Panagora Asset Management Inc , Deciphera Pharmaceuticals , Deciphera Pharmaceuticals Stock , Free Report , Deciphera Pharmaceutical , Financial Group , Get Free Report , Universal Asset Management , Asset Management , Deciphera Pharmaceuticals Daily ,

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives $23.87 Consensus PT from Analysts

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives $23.87 Consensus PT from Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United States , Stifel Nicolaus , Deciphera Pharmaceuticals Stock Performance , Deciphera Pharmaceuticals , Dimensional Fund Advisors , Jpmorgan Chase Co , Deerfield Management Companylp Series , Analyst Recommendations For Deciphera Pharmaceuticals , Institutional Trading Of Deciphera Pharmaceuticals , Goldman Sachs Group Inc , News Ratings For Deciphera Pharmaceuticals Daily , Deciphera Pharmaceuticals Inc , Armistice Capital , Frazier Life Sciences Management , Get Free Report , Sachs Group , Fund Advisors , Get Free , Deciphera Pharmaceuticals Daily ,

Deciphera Pharmaceuticals (NASDAQ:DCPH) Rating Reiterated by Guggenheim

Guggenheim reaffirmed their neutral rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. Other analysts have also recently issued research reports about the company. Jonestrading restated a hold rating and set a $25.60 target price on shares of Deciphera Pharmaceuticals in a report […] ....

United States , Stifel Nicolaus , Deutsche Bank , Jefferies Financial Group , Deciphera Pharmaceuticals Price Performance , Deciphera Pharmaceuticals Inc , Analyst Recommendations For Deciphera Pharmaceuticals , Hedge Funds Weigh In On Deciphera Pharmaceuticals , Deciphera Pharmaceuticals , News Ratings For Deciphera Pharmaceuticals Daily , Panagora Asset Management Inc , Deerfield Management Companylp Series , Free Report , Financial Group , Get Free Report , Asset Management , Forest Capital Management , Deciphera Pharmaceuticals Daily , Nasdaq Dcph , Reiterated Rating ,